Cartesian Therapeutics (RNAC) Receivables - Other (2020 - 2024)

Cartesian Therapeutics (RNAC) has 5 years of Receivables - Other data on file, last reported at $980000.0 in Q3 2024.

• On a quarterly basis, Receivables - Other fell 47.73% year-over-year to $980000.0 in Q3 2024; TTM through Sep 2024 was $980000.0, a 47.73% decrease from a year earlier, with the FY2023 full-year figure at $3.0 million, down 5.72% from the prior year.
• Receivables - Other for Q3 2024 stood at $980000.0, down from $3.5 million in the prior quarter.
• Over the last five years, Receivables - Other for RNAC reached as high as $3.5 million in Q2 2024 and fell as low as $100000.0 in Q3 2021.
• Historically, Receivables - Other has averaged $1.6 million across 5 years, with a median of $1.1 million in 2023.
• Across the five-year window, Receivables - Other tumbled 80.0% in 2021 and jumped 229.1% in 2024, its largest moves.
• Year by year, Receivables - Other stood at $1.0 million in 2020, then sank by 90.0% to $100000.0 in 2021, then soared by 3062.0% to $3.2 million in 2022, then declined by 5.72% to $3.0 million in 2023, then slumped by 67.13% to $980000.0 in 2024.
• Per Business Quant data, the three most recent Receivables - Other figures were $980000.0 in Q3 2024, $3.5 million in Q2 2024, and $2.4 million in Q1 2024.